BAR12:考虑生产变更的细胞疗法贝叶斯自回归1-2期设计
细胞疗法早期剂量探索试验中可能发生生产变更(tweak),影响剂量-反应分布。本文提出BAR12贝叶斯自回归1-2期设计,采用一阶自回归模型与尖峰-平板先验分别对应变更前后毒性及疗效参数。模拟显示BAR12在正确剂量选择概率、最优剂量患者分配及安全/无效剂量监测效率上优于传统设计。
要点
- 细胞疗法试验中的生产变更需在统计设计中予以考虑。
- BAR12采用一阶自回归模型与尖峰-平板先验处理变更前后参数。
- 模拟显示BAR12在剂量选择与患者分配上优于传统方法。
核心结论
- BAR12设计在考虑生产变更的1-2期细胞疗法试验中具有更优的操作特性。
研究设计与样本
- 提出贝叶斯自回归1-2期设计(BAR12),采用一阶自回归模型与尖峰-平板先验,先验成分对应变更前后毒性和疗效参数分布。
- 在广泛剂量-反应函数下进行模拟,比较BAR12与假设变更无影响用全部数据或忽略变更前数据的传统1-2期设计。
主要发现
- 模拟显示BAR12正确剂量选择概率更高。
- BAR12将更多患者分配到最优剂量。
- BAR12对不安全或无效剂量的监测更高效。
临床怎么用
- 在细胞疗法早期剂量探索中,若存在生产变更,可采用BAR12设计以兼顾变更前后数据并优化剂量选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An early phase dose-finding trial of a new cell therapy may involve one or more manufacturing modifications made during the trial, known as "tweaks," to improve the cell product quality. For example, a tweak may change the cell culture duration, cytokine cocktail, or donor criteria. Ideally, a tweak can be done without changing the treatment so much that the trial must be restarted as if the treatment were entirely new. However, a statistical design still should account for changes in the dose-response distribution due to the tweak. For such settings, we propose a Bayesian AutoRegressive Phase 1-2 (BAR12) design that accounts for manufacturing tweaks during a phase 1-2 trial by using a first order autoregressive model with spike-and-slab priors having components corresponding to pre- and post-tweak distributions of toxicity and efficacy parameters. Simulations under a broad range of dose-response functions were conducted to compare BAR12 to conventional phase 1-2 designs that either assume the tweak had no effect and use all available data, or ignore the pre-tweak data. The simulations show that BAR12 has superior operating characteristics, including higher probabilities of correct dose selection, allocation of more patients to optimal doses, and more efficient monitoring for identifying unsafe or ineffective doses.
引用
- Yang CH, Thall PF, Marin D, et al. BAR12: Bayesian Autoregressive Phase 1-2 Design for Cell Therapy Trials With Manufacturing Changes. Stat Med. 2026. PMID: 42009580. doi:10.1002/sim.70551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。